Menu Close

CAR-T Cell Therapy Combination Shows Promise in Relapsed/Refractory Leukemia

Using chimeric antigen receptor (CAR)-T cell therapy plus Imbruvica (ibrutinib), a targeted treatment, could improve outcomes in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to study findings presented during the 2018 … (본문 전체 12/4/2018 11:09 PM)